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Abstract 
Purpose: To investigate the re-endothelialization potential of erythropoietin (EPO) following 
microvascular anastomosis in rat femoral artery. 
Methods: Ninety-six male Sprague-Dawley rats weighing between 300 g and 320 g were allocated 
randomly into two groups (control and EPO, n = 48). Left femoral artery microvascular anastomosis was 
performed in the rats. The control group was given 0.5 mL of 0.09 % NaCl subcutaneously 48 h post-
operatively while the EPO group was given 150 U/kg recombinant human erythropoietin subcutaneously 
48 h post-operatively. Tissue was harvested from each group after 1, 3, 5, and 7 days. All of the rats 
were sacrificed for morphometric analysis. Each arterial segment was analyzed morphometrically using 
Clemex Image Analysis software by a single examiner. The cross-sectional area of the media and 
neointima was measured and the intima/media ratio was calculated. Hematocrit measurement was 
carried out for all the rats. 
Results: The I/M ratio differed significantly (p < 0.05) between the control and erythropoietin groups, at 
all time-points. The hematocrit was significantly (p < 0.05) lower in the control group than in the 
erythropoietin groups on day 7, but not on the other days. 
Conclusion: This study demonstrates that erythropoietin markedly inhibits neointima formation with 
accelerated re-endothelialization in rat femoral arteries following microvascular anastomosis. 
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Microsurgical procedures require much labor, 
time, and funding. Problems that arise with 
anastomosis account for most of the 
complications that follow microsurgical 
procedures. Delayed re-endothelialization at the 
anastomosis line leads to thrombus formation 
and anastomotic blockage for various reasons. 
The main contributor to a successful 
microsurgical procedure is safe vessel 
anastomosis. The faster the healing of the 
anastomosis is, the fewer complications that 
result. 
 
There are many growth factors and hormones 
that stimulate angiogenesis. Vascular endothelial 
growth factor (VEGF) is an important growth 
factor with strong mitogenic effects on 
endothelial cells [1-4]. Erythropoietin (EPO) is a 
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critical regulator of the proliferation of erythroid 
and endothelial precursors, but its role as a 
potential re-endothelialization agent in 
microvascular anastomosis is unclear [5-8]. This 
study investigated the effect of erythropoietin on 




The study was approved by the Ethics 
Committee of the Experimental Medical 
Research and Application Center of Selçuk 
University and the Principles of Laboratory 
Animal Care (NIH publication No. 85-23, revised 
1985). We used 96 male Sprague–Dawley rats 
weighing 300 – 320 g. The animals were kept in 
the same room at 22 ± 1 °C under standard 
physical conditions and fed the same standard 
diet. 
 
For the experiment, each animal was given 
intramuscular anesthesia with 35 mg/kg 
ketamine (Ketalar® 50 mg/mL vial, Pfizer) and 5 
mg/kg xylazine (Rompun® vial, Bayer). The 
animal was positioned on its back on the 
operating table. After shaving the left inguinal 
area, the skin was cleaned with antiseptic 
solution and a 2-cm incision was made on the left 
inguinal crease with a no. 15 blade. After careful 
dissection, the femoral neurovascular bundle 
was identified. The femoral artery was exposed 
using an 8× loupe and clamped with an Acland 
approximator (00409A; S&T, Switzerland), then 
cut vertically and 0.1 % bupivacaine (Marcaine, 
AstraZeneca®) was applied locally to reduce 
vessel spasm.  
 
After cleaning the adventitia, two tension sutures 
were inserted at 120° angle with 10/0-75 μm, 
round polyamide needles (Ethicon Ethilon-
W2850-J&J). These sutures were hung around 
the Acland approximator. After repairing the 
anterior wall, the approximator was rotated 180 
degrees. Then, the posterior wall was repaired. 
After fixing the approximator, the microclamp 
was removed. An average of six sutures was 
inserted for each anastomosis. Then, hemostasis 
was performed and the skin was closed with 4/0 
silk sutures. The mean anastomosis time was 30 
min, while the total operating time was 40 min for 
a rat. The animals were divided into control (n = 
48) and EPO (n = 48) groups. The control group 
was given 0.5 mL of 0.09 % NaCl 
subcutaneously 48 h post-operatively. The EPO 
group was given 150 U/kg recombinant human 
erythropoietin (Eprex 2000 IU rHuEPO vial) 
subcutaneously 48 h post-operatively.  
 
Tissue was harvested from each group after 1, 3, 
5, and 7 days. For this, each animal was again 
anesthetized with intramuscular ketamine and 
xylazine, as described above, and placed in the 
supine position on the operating table. After 
removing the sutures from the wound, the 
anastomosis area was dissected with the aid of 
an 8×190-mm loupe (Prismen Lupe KS, Carl 
Zeiss, Germany). A 1-mm length was taken from 




Blood samples collected from carotid 
arteries.The Blood samples were taken from all 
animals and the hematocrit was determined 





The tissue samples were fixed in 10 % 
formaldehyde, followed by Autotechnicon 
(Shandon Citadel 2000). After 24 h they were 
embedded in paraffin blocks vertically and 5-µm 
cross-sections were prepared from these paraffin 
blocks using a microtome. The cross-sections 
were stained with Verhoeff–Van Gieson stain 
and examined using a Nikon Eclipse E400 
microscope.  
 
They were photographed with a Nikon Coolpix 
5000 digital camera. The photographs were 
analyzed using Clemex Image Analysis and the 
areas of the tunica intima and media were 




The data were analyzed using Statistical 
Package for the Social Sciences (SPSS), version 
16.0, for Windows. One-sample Kolmogorov–
Smirnov test was used to analyze the distribution 
of continuous variables.  Continuous variables 
with normal distributions were compared 
between the two groups using Students t-test. All 





The results (Figs 1 – 3) of our investigation can 
be summarized as follows. First, in the early 
stage (1 – 3 days), EPO reduced intimal 
hyperplasia by increasing endothelialization at 
the microvascular anastomosis line. Second, at 5 
– 7 days, intimal hyperplasia is insignificant due 
to the completion of endothelialization. Third, the 
hematocrit did not increase significantly following 
the use of EPO in the early stage (1 – 3 days), 
but increased significantly at 5 – 7 days. 
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Figure 1: Appearance of control group on day 7 after 





Figure 2: Appearance of the erythropoietin group on 




Figure 3: Tunica intima and tunica media areas. I/M 
(a/b) = 0.78 
 
The mean intima/media (I/M) ratio, hematocrit 
and p-values of all groups are shown in Table 1. 
I/M ratio differed significantly (p < 0.05) between 
control and erythropoietin groups, at all-time 
points. Hematocrit was significantly (p < 0.05) 
lower in the control group than in the 





The role of microvascular surgery in plastic 
surgery has been increasing gradually. The main 
condition for a successful microsurgical 
procedure is a safe vessel anastomosis. The 
faster the healing of the anastomosis is, the 
fewer complications there will be. The results of 
our investigation can be summarized as follows: 
This study supports other recent studies of 
angiogenic factors and underlines the importance 
of EPO in microvascular surgery. Based on these 
positive effects, we believe that EPO will reduce 
complications and increase the success rate of 
microsurgery. 
 
Table 1: Group statistics for I/M and hematocrit 
 
Parameter Day Erythropoietin  
(mean ± SD) 
Control 
(mean ± SD) 
P-valuea 
































a Student’s t-test 
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Many growth factors and hormones stimulate 
angiogenesis [1-3]. VEGF is an important growth 
factor that has a strong mitogenic effect on 
endothelial cells [4]. There are many other 
angiogenic growth factors and hormones, but 
only a limited number of studies have examined 
them. EPO is one of these factors. Cytokines and 
especially EPO-related hematopoiesis are 
thought to play a role in angiogenesis as 
hematopoietic and endothelial cell lines are 
derived from the same common ancestor [5-8]. 
 
Ribatti et al showed that cytokines previously 
thought to be specific for the hematopoietic 
system affect endothelial cell functions, including 
angiogenesis [9]. However, there are few studies 
of the angiogenic effects of EPO compared to 
other angiogenic factors (VEGF and fibroblast 
growth factor (FGF)). VEGF is the most 
important angiogenic factor [10]. 
 
In a study of myocardial tissue cultures from 111 
patients, Jaquet et al showed that the capillary 
growth rate was 220 % with VEGF versus 230 % 
with EPO [11]. This study showed that EPO was 
as effective as VEGF and supports our results. 
However, Nitta et al stated that EPO increased 
DNA synthesis in cattle glomerular endothelial 
cell cultures and this stimulated VEGF synthesis 
[12]. EPO increases the synthesis of endothelin 
1, via thrombin and angiotensin, two potential 
stimulators of ET-1 [5,6}. Salani et al studied the 
role of ET-1 in angiogenesis in human umbilical 
vein endothelial cell (HUVEC) cultures in 
comparison to VEGF, and found that ET-1 
increases the angiogenesis induced by VEGF 
[14]. 
 
The potential interaction between VEGF and ET-
1 was also investigated by Matsuura et al, who 
proved that VEGF increases the ET-1 secretion 
in endothelial cells [13]. All of these studies show 
that many factors interact in angiogenesis. In 
addition to the direct angiogenic effect of EPO, it 
also has indirect angiogenic effects by increasing 
the production of other factors. 
 
Vascular injuries cause an increase in 
extracellular matrix, the proliferation of smooth 
muscle cells, and formation of neointima via cell 
proliferation and migration [15,16]. Endothelial 
cells inhibit intimal hyperplasia by regulating the 
growth of smooth muscle cells [15,17]. However, 
rapid re-endothelialization inhibits intimal 
hyperplasia via thrombus formation [18-23]. 
These data suggest that there is a reverse 
relationship between intimal hyperplasia and re-
endothelialization.  
 
Based on this information, many studies 
evaluating re-endothelialization have measured 
the neointima and media, and their ratio has 
been accepted as an indicator of re-
endothelialization [20-24]. These values are 
calculated from a histomorphometric analysis 
and the resulting numerical data indicate that it is 
a sensitive and an effective method. We used 
Clemex Image Analysis for the morphometric 
analysis. Other techniques used to evaluate re-
endothelialization are macroscopic 
photomicrography with Evans blue staining and 
fluorescence microscopy [21,23]. These 
techniques are more subjective than 
morphometric analysis. Morphometric field 
analysis is useful in the rat femoral artery 
reanastomosis model because the injury site in 
the endothelium is so small that it cannot be 
quantified sensitively using photomicrographic 
techniques. 
 
Comparing the I/M ratios calculated in the 
morphometric analysis, it was found that the 
intima and media areas were lower than in the 
other groups, but their ratio (I/M) was higher. 
This shows that the tunica intima responds more 
rapidly and intensely to the injury at the 
anastomosis line than the tunica media. 
 
In a histological study, Weinstein et al showed 
that elastic and muscular elements do not 
regenerate like the endothelium, and the 
response of the media layer to healing is slower 
than the intima [25]. Since the intimal hyperplasia 
in the control group was lower than in the 
erythropoietin group on day 1, it is thought that 
even a single dose of EPO has powerful positive 
effects on the endothelium. In both groups, the 
intima and media areas increased on the third 
day, while their ratio decreased. This showed 
that the intimal hyperplasia decreased in both the 
control and erythropoietin groups. 
 
On the third day, the intima was thinner than on 
the first day; therefore, the re-endothelialization 
activity was rapid on the third day [25,26]. Less 
intimal hyperplasia was seen with the EPO 
activity in this group. On days 5 and 7, there was 
no substantial increase in the intima and the I/M 
ratio was low because re-endothelialization was 
complete [26-28]. The I/M values were significant 
in all groups (p < 0.05). This showed that 
erythropoietin decreased intimal hyperplasia by 
increasing re-endothelialization. 
 
In this study, EPO was administered to the 
experimental animals subcutaneously at 48-hour 
intervals. Macdougall et al reported that the 
subcutaneous administration of EPO was the 
best treatment [29]. Following subcutaneous 
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injection, to maintain a high EPO concentration in 
blood, the injection must be repeated every 48 h. 
The hemoglobin increases markedly when EPO 
is used in chronic renal failure for long periods 
[30]. The main side effect is hypertension in 
patients treated with EPO [31]. However, lower-
dose EPO treatment and careful selection of the 
hemoglobin target decreases the incidence of 
hypertension [31]. In a study of healthy 
individuals, McMahon et al did not observe 
hypertension in any of the subjects [32]. Saray et 
al reported that there was no significant 
difference in arterial blood pressure and 
hematocrit with short-term EPO use, but there 
was a significant difference with long-term use 
[33]. Therefore, we used low-dose EPO. In our 
study, the hematocrit was minimally higher in 
experimental groups 1 to 3 than in the controls, 
but the difference was not significant, while the 
difference was significant in group 4. These 
values might have resulted from the low-dose, 




The findings of this study support other recent 
reports of angiogenic factors and underline the 
importance of EPO in microvascular surgery. It 
appears that EPO has two positive effects on 
microsurgery. First, it increases endothelia-
lization on the anastomosis line and, secondly, it 
enhances flap vascularity. Based on these 
positive effects, it seems likely that EPO will 
reduce complications and increase the success 
rate of microsurgery. In this way, patients will not 
lose the opportunity for treatment, while 
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